Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 279

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

PD-L1 is highly expressed in Enzalutamide resistant prostate cancer

Open access
Bishop, Jennifer L., Sio, Alexander, Angeles, Arkhjamil, Roberts, Morgan E., Azad, Arun A., Chi, Kim N., Zoubeidi, Amina·2015·Oncotarget
DOI 10.18632/oncotarget.2703
Open this paper in CoChat — free account

Abstract

// Jennifer L. Bishop 1 , Alexander Sio 1 , Arkhjamil Angeles 1 , Morgan E. Roberts 2 , Arun A. Azad 3 , Kim N. Chi 3 and Amina Zoubeidi 1,4 1 Vancouver Prostate Centre, Vancouver, BC, Canada 2 Department of Microbiology and Immunology, University of British Columbia, Vancouver, BC, Canada 3 Department of Medicine, Division of Medical Oncology, BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada 4 Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada Correspondence: Amina Zoubeidi, email: // Keywords :Enzalutamide resistant CRPC, Immunotherapy, PD-L1 Received : October 30, 2014 Accepted : November 06, 2014 Published : November 06, 2014 Abstract Efficacy of Enzalutamide (ENZ) in castration resistant prostate cancer (CRPC) patients is short-lived. Immunotherapy like T cell checkpoint blockade may improve patient survival. However, when and where checkpoint molecules are expressed in CRPC and whether immune evasion is a mechanism of ENZ resistance remains unclear. Thus, we investigated whether clinically relevant immunotherapy targets, specifically PD-L1/2 , PD-1 and CTLA-4, are upregulated in ENZ resistant (ENZR) patients and in a pre-clinical model of ENZ resistance. We show for the first time that patients progressing on ENZ had significantly increased PD-L1/2 + dendritic cells (DC) in blood compared to those naïve or responding to treatment, and a high frequency of PD-1 + T cells. These data supported our pre-clinical results, in which we found significantly increased circulating PD-L1/2 + DCs in mice bearing ENZR tumors compared to CRPC, and ENZR tumors expressed significantly increased levels of tumor-intrinsic PD-L1. Importantly, the expression of PD-L1 on ENZR cells, or the ability to modulate PD-L1/2 + DC frequency, was unique to ENZR cell lines and xenografts that did not show classical activation of the androgen receptor. Overall, our results suggest that ENZ resistance is associated with the strong expression of anti-PD-1 therapy targets in circulating immune cells both in patients and in a pre-clinical model that is non-AR driven. Further evaluation of the contribution of tumor vs. immune cell PD-L1 expression in progression of CRPC to anti-androgen resistance and the utility of monitoring circulating cell PD-L1 pathway activity in CRPC patients to predict responsiveness to checkpoint immunotherapy, is warranted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.2703

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 279

Metadata

Authors
Bishop, J. L., Sio, A., Angeles, A., Roberts, M. E., Azad, A. A., Chi, K. N., & Zoubeidi, A.
Venue
Oncotarget
Publisher
Impact Journals, LLC
Published
2014-11-06
Volume
6
Issue
1
Pages
234-242
ISSN
1949-2553 (ISSN-L)
DOI
10.18632/oncotarget.2703
OpenAlex
W1582446028
Cited by
279
References
33
FWCI
17.69
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PD-L1 is highly expressed in Enzalutamide resistant prostate cancer. https://app.cochat.ai/papers/10.18632/oncotarget.2703
The paper
Bishop, J. L., Sio, A., Angeles, A., Roberts, M. E., Azad, A. A., Chi, K. N., & Zoubeidi, A. (2015). PD-L1 is highly expressed in Enzalutamide resistant prostate cancer. Oncotarget. https://doi.org/10.18632/oncotarget.2703

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.